Dong-A Socio Holdings Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Dong-A Socio Holdings Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Dong-A Socio Holdings Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Dong-A Socio Holdings Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Dong-A Socio Holdings Co Ltd (Dong-A Socio Holdings), a subsidiary of Dong-A Socio Group, operates as a holding company focused on managing its affiliates and providing business management services. It operates through its subsidiaries. The company manages Dong-A ST, which develops ethical drugs and new global treatments, and Dong-A Pharmaceutical, dedicated to innovative healthcare products like Bacchus and OTC items. ST Pharm offers cGMP services for drug development, while STgen Bio functions as a global CDMO. Dong-A Chammed specialises in ENT medical devices, and Dong-A Otsuka leads in functional beverages. Yongma Logis excels in logistics for the Health and Beauty sector, and Soo Seok produces food packaging. Korea Sinto enhances industrial technology, Dongcheonsu focuses on high-quality beverages, and ABEN Engineering specializes in healthcare construction. DA Information provides IT services across the group. Dong-A Socio Holdings is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
64 Cheonho-daero, Seoul, 02587
Website
www.donga.co.kr
Telephone
82 2 9208114
No of Employees
273
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
000640 (KRX)
Revenue (2024)
$1.0B
7.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
56.7%
(2024 vs 2023)
Market Cap*
$355.7M
Net Profit Margin (2024)
XYZ
46.2%
(2024 vs 2023)
* As of and is in US$
Dong-A Socio Holdings Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Prescription Drugs: | Panpyrin |
| Anti-Cancer | Circulan |
| Anti-Fungal | Bigen Cream Tone |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Contracts/Agreements | In July, the company entered into an agreement to acquire 49% joint venture stake from Meiji Seika Pharma. |
| 2019 | Regulatory Approval | In December, the company received US FDA's IND approval for its ST pharma for colorectal cancer treatment STP1002. |
| 2019 | Contracts/Agreements | In October the company entered into an agreement with Incheon Techno Park to foster the bio-industry. |
Competitor Comparison
| Key Parameters | Dong-A Socio Holdings Co Ltd | Chong Kun Dang Pharmaceutical Corp. | Oscotec Inc | SeouLin Bioscience Co Ltd | Beijing Hanmi Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | China |
| City | Seoul | Seoul | Seongnam | Seongnam | Beijing |
| State/Province | - | Seoul | - | - | Beijing |
| No. of Employees | 273 | 2,336 | 35 | 110 | 1,400 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kim Min-Young | Chief Executive Officer; Director | Executive Board | 2024 | - |
| Ko Seung-Hyun | Director; Head-Management Support Office | Executive Board | 2021 | - |
| Hyun Min Lee | Director; Head- Business Planning Office | Executive Board | - | - |
| Kwon Kyoung-Bae | Chairman | Non Executive Board | 2023 | - |
| Keum Young-Sam | Director | Non Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer